Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Materials (Basel, Switzerland)
|
March 10, 2022
Flexible and Stretchable Bioelectronics
Chandani Chitrakar, Eric Hedrick, Lauren Adegoke, et al.
Seminars in Oncology
|
February 1, 2017
Rituximab: Ongoing and future clinical development
Antonio J Grillo-López, Eric Hedrick, Michelle Rashford, et al.
Seminars in Oncology
|
February 14, 2002
Rituximab: ongoing and future clinical development
Antonio J Grillo-López, Eric Hedrick, Michelle Rashford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2008
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)
Axel Grothey, Mary M Sugrue, David M Purdie, et al.
Oncotarget
|
August 29, 2015
Specificity protein (Sp) transcription factors and metformin regulate expression of the long non-coding RNA HULC
Shruti U Gandhy, Parisa Imanirad, Un-Ho Jin, et al.
Haematologica
|
April 21, 2022
A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib
Anthony R Mato, Boxiong Tang, Soraya Azmi, et al.
Cancer
|
September 16, 2003
Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma
Eunice S Wang, David J Straus, Julie Teruya-Feldstein, et al.
Ejhaem
|
February 23, 2023
A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States
Anthony Mato, Boxiong Tang, Soraya Azmi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2008
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study
Howard S Hochster, Lowell L Hart, Ramesh K Ramanathan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 10, 2012
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies
Ranjana H Advani, Joseph J Buggy, Jeff P Sharman, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Materials (Basel, Switzerland)
|
March 10, 2022
Flexible and Stretchable Bioelectronics
Chandani Chitrakar, Eric Hedrick, Lauren Adegoke, et al.
Seminars in Oncology
|
February 1, 2017
Rituximab: Ongoing and future clinical development
Antonio J Grillo-López, Eric Hedrick, Michelle Rashford, et al.
Seminars in Oncology
|
February 14, 2002
Rituximab: ongoing and future clinical development
Antonio J Grillo-López, Eric Hedrick, Michelle Rashford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2008
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)
Axel Grothey, Mary M Sugrue, David M Purdie, et al.
Oncotarget
|
August 29, 2015
Specificity protein (Sp) transcription factors and metformin regulate expression of the long non-coding RNA HULC
Shruti U Gandhy, Parisa Imanirad, Un-Ho Jin, et al.
Haematologica
|
April 21, 2022
A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib
Anthony R Mato, Boxiong Tang, Soraya Azmi, et al.
Cancer
|
September 16, 2003
Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma
Eunice S Wang, David J Straus, Julie Teruya-Feldstein, et al.
Ejhaem
|
February 23, 2023
A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States
Anthony Mato, Boxiong Tang, Soraya Azmi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2008
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study
Howard S Hochster, Lowell L Hart, Ramesh K Ramanathan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 10, 2012
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies
Ranjana H Advani, Joseph J Buggy, Jeff P Sharman, et al.
Page
of 2